Emgality (galcanezumab-gnlm) — Point32Health
episodic cluster headache
Initial criteria
- Diagnosis of episodic cluster headache
- Patient age ≥ 18 years
- Medication will not be used in combination with another CGRP antagonist used for migraine prevention (e.g., Aimovig, Emgality, Ajovy, Nurtec ODT, Qulipta)
Reauthorization criteria
- Drug is prescribed for the same condition as initial request
- Patient has experienced a positive response to therapy
- Medication will not be used in combination with another CGRP antagonist used for the same condition
Approval duration
12 months